Intrasense (ALINS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Intrasense (ALINS) has a cash flow conversion efficiency ratio of 2.505x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.92 Million ≈ $-3.41 Million USD) by net assets (€-1.17 Million ≈ $-1.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Intrasense - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Intrasense's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Intrasense debt and liabilities for a breakdown of total debt and financial obligations.
Intrasense Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Intrasense ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PT Winner Nusantara Jaya Tbk
JK:WINR
|
-0.010x |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
-1.513x |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
-0.151x |
|
Peregrine Gold Ltd
AU:PGD
|
-0.292x |
|
Intelicanna Ltd
TA:INTL
|
-0.023x |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
-0.096x |
|
MEKICS Co Ltd
KQ:058110
|
-0.012x |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Intrasense (2008–2024)
The table below shows the annual cash flow conversion efficiency of Intrasense from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see ALINS market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €1.65 Million ≈ $1.93 Million |
€-3.73 Million ≈ $-4.36 Million |
-2.256x | -439.26% |
| 2023-12-31 | €7.29 Million ≈ $8.52 Million |
€-3.05 Million ≈ $-3.56 Million |
-0.418x | +57.06% |
| 2022-12-31 | €2.01 Million ≈ $2.35 Million |
€-1.96 Million ≈ $-2.29 Million |
-0.974x | -438.00% |
| 2021-12-31 | €4.99 Million ≈ $5.83 Million |
€-903.00K ≈ $-1.06 Million |
-0.181x | +9.72% |
| 2020-12-31 | €2.15 Million ≈ $2.52 Million |
€-432.00K ≈ $-505.05K |
-0.201x | -121.44% |
| 2019-12-31 | €573.00K ≈ $669.90K |
€536.00K ≈ $626.64K |
0.935x | +166.67% |
| 2018-12-31 | €2.17 Million ≈ $2.54 Million |
€761.69K ≈ $890.50K |
0.351x | -39.39% |
| 2017-12-31 | €1.34 Million ≈ $1.56 Million |
€773.91K ≈ $904.79K |
0.579x | +44.40% |
| 2016-12-31 | €2.26 Million ≈ $2.64 Million |
€905.07K ≈ $1.06 Million |
0.401x | +196.26% |
| 2013-12-31 | €3.59 Million ≈ $4.20 Million |
€-1.50 Million ≈ $-1.75 Million |
-0.416x | -15.27% |
| 2012-12-31 | €5.40 Million ≈ $6.31 Million |
€-1.95 Million ≈ $-2.28 Million |
-0.361x | +85.81% |
| 2011-12-31 | €123.29K ≈ $144.14K |
€-313.74K ≈ $-366.80K |
-2.545x | -10155.88% |
| 2008-12-31 | €4.90 Million ≈ $5.73 Million |
€124.00K ≈ $144.97K |
0.025x | -- |
About Intrasense
Intrasense S.A. designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. It offers the Myriad platform, a visualization solution that provides a suite of clinical tools and artificial intelligence algorithms for prostate, lung, and brain pathologies; and the Liflow solution, an oncological imaging platform that… Read more